Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
20% albumin versus Voluven as CPB prime in CABG surgery
IRCT20220410054470N1Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2022
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of albumin (human) and Volulyte in coronary arteriosclerosis (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Interleukin 6, Drainage rate after surgery and 1 more. Started Apr 2022; status: completed.
02
Drugs
albumin (human)Volulyte
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20220410054470N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220410054470N1.